SCHEMBL2660673

SCHEMBL2660673

CCN1Cc2nc3c(-c4ccc(F)cc4F)c(F)ccc3c(N)c2C1=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 2/20 0.34
▸ HDAC2 Q92769 2/20 0.34
▸ MAPK13 O15264 3/20 0.33
▸ MAPK12 P53778 3/20 0.33
▸ MAPK11 Q15759 3/20 0.33
▸ MAPK14 Q16539 3/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ PDE5A O76074 4/20 0.33
▸ HTR2A P28223 1/20 0.32
▸ GRM2 Q14416 1/20 0.32
▸ GRIA2 P42262 1/20 0.32
▸ GABRG2 P18507 2/20 0.32
▸ GABRB3 P28472 2/20 0.32
▸ GABRA2 P47869 2/20 0.32
▸ PTPN11 Q06124 1/20 0.32
▸ PDE4A P27815 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ DPP4 P27487 1/20 0.31
▸ DPP8 Q6V1X1 1/20 0.31
▸ DPP9 Q86TI2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2661405 0.88 GABRG2 (0.42) PDE5AGRM2GABRG2GABRB3GABRA2
SCHEMBL4923522 0.88 PDE5A (0.34) PDE5AGRM2GABRG2GABRB3GABRA2
SCHEMBL2655495 0.88 GABRG2 (0.43) PDE5AGABRG2GABRB3GABRA2DPP4
SCHEMBL2656331 0.83 PDE5A (0.40) PDE5AGABRG2GABRB3GABRA2DPP4
SCHEMBL2658808 0.83 GABRG2 (0.44) PDE5AGRM2GABRG2GABRB3GABRA2
SCHEMBL2657010 0.83 GABRG2 (0.51) PDE5AGABRG2GABRB3GABRA2MAPT
SCHEMBL2657693 0.82 LCK (0.34) —
SCHEMBL2661341 0.82 GABRG2 (0.38) PDE5AGABRG2GABRB3GABRA2
SCHEMBL2661635 0.82 GABRG2 (0.49) PDE5AGABRG2GABRB3GABRA2
SCHEMBL2656693 0.82 PDE5A (0.34) PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF HDAC1 903/4885HDAC2 808/4885MAPK13 3389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback